journal
MENU ▼
Read by QxMD icon Read
search

Biology of Blood and Marrow Transplantation

journal
https://www.readbyqxmd.com/read/28344060/basal-cd34-cell-count-predicts-peripheral-blood-stem-cell-mobilization-in-healthy-donors-after-administration-of-g-csf-a-longitudinal-prospective-observational-single-center-cohort-study
#1
Massimo Martino, Mercedes Gori, Annalisa Pitino, Massimo Gentile, Antonia Dattola, Antonella Pontari, Ernesto Vigna, Tiziana Moscato, Anna Grazia Recchia, Santina Barilla', Giovanni Tripepi, Fortunato Morabito
A longitudinal, prospective, observational, single-center, cohort study on healthy donors (HDs) was designed to identify predictors of CD34+ cells on day 5 with emphasis on the predictive value of the basal CD34+ cell count. As potential predictors of mobilization, age, sex, body weight, height, blood volume as well as white blood cell count, peripheral blood (PB) mononuclear cells, platelet count, hematocrit, and hemoglobin levels were considered. Two different evaluations of CD34+ cell counts were determined for each donor: baseline (before granulocyte colony-stimulating factor [G-CSF] administration) and in PB after G-CSF administration on the morning of the fifth day (day 5)...
March 24, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28344059/gastrointestinal-toxicity-systemic-inflammation-and-liver-biochemistry-in-allogeneic-haematological-stem-cell-transplantation
#2
K Jordan, P Pontoppidan, H Uhlving, K Kielsen, D G Burrin, S Weichendorff, I J Christensen, M H Jørgensen, C Heilmann, H Sengeløv, K Müller
INTRODUCTION: Liver toxicity is frequently seen in relation to allogeneic hematopoietic stem cell transplantation (HSCT), but pathogenesis and the risk factors are poorly understood. The purpose of this study was to investigate associations between liver toxicity, gastrointestinal toxicity and levels of immune regulating cytokines during the early post-transplant period. METHODS: We prospectively included 81 children and adults undergoing HSCT after myeloablative conditioning...
March 23, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28344058/possible-impact-of-cmv-specific-cd8-t-cells-on-immune-reconstitution-and-conversion-to-complete-donor-chimerism-after-allogeneic-sct
#3
Justyna Ogonek, Pavankumar Varanasi, Susanne Luther, Patrick Schweier, Wolfgang Kühnau, Gudrun Göhring, Elke Dammann, Michael Stadler, Arnold Ganser, Sylvia Borchers, Ulrike Koehl, Eva M Weissinger, Lothar Hambach
Complete donor chimerism is strongly associated with complete remission after allogeneic stem cell transplantation (allo-SCT) in patients with hematological malignancies. Donor-derived allo-immune responses are eliminating the residual host hematopoiesis and thereby mediate the conversion to complete donor chimerism. Recently, CMV reactivation has been described to enhance overall T-cell reconstitution, to increase graft-versus-host disease (GvHD) incidence and to reduce the leukemia relapse risk. However, the link between CMV and allo-immune responses is still unclear...
March 23, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28344057/ruxolitinib-as-salvage-therapy-in-steroid-refractory-acute-graft-versus-host-disease-in-pediatric-hematopoietic-stem-cell-transplant-patients
#4
Pooja Khandelwal, Ashley Teusink-Cross, Adam S Nelson, Christopher E Dandoy, Javier El-Bietar, Rebecca A Marsh, Ashish R Kumar, Michael S Grimley, Stella M Davies, Sonata Jodele, Kasiani C Myers
We describe our retrospective clinical experience with ruxolitinib for steroid-refractory acute graft versus host disease (GVHD) in pediatric allogeneic hematopoietic stem cell transplant (HSCT) patients. Ruxolitinib was administered orally at 5 mg twice daily for children ≥ 25 kg or 2.5 mg twice daily if < 25 kg. We excluded patients who received new immune suppressive agents within two weeks before initiation of ruxolitinib from response analysis. Patients were called a treatment failure if ruxolitinib was stopped before completion of 4 weeks of therapy due to adverse effects and not because of progression of acute GVHD...
March 23, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28336325/allogeneic-hematopoietic-stem-cell-transplantation-is-underutilized-in-older-patients-with-myelodysplastic-syndromes
#5
Bartlomiej M Getta, Ashwin Kishtagari, Patrick Hilden, Martin S Tallman, Molly Maloy, Patrick Gonzales, Hugo Castro-Malaspina, Miguel-Angel Perales, Sergio Giralt, Roni Tamari, Virginia Klimek
Allogeneic hematopoietic stem cell transplantation (HCT) is the only curative treatment for myelodysplastic syndrome (MDS). The proportion of MDS patients referred for transplant evaluation, those undergoing transplantation and the reasons for not undergoing transplant are unknown. In this retrospective analysis, pre-defined HCT eligibility and indications criteria were applied to 362 unselected patients with newly diagnosed MDS seen by Leukemia faculty between 2008 and 2015 at Memorial Sloan Kettering Cancer Center...
March 20, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28323004/fresh-or-cryopreserved-cd34-selected-mobilized-peripheral-blood-stem-and-progenitor-cells-for-the-treatment-of-poor-graft-function-following-allogeneic-hematopoietic-cell-transplantation
#6
Armin Ghobadi, Mark A Fiala, Giridharan Ramsingh, Feng Gao, Camille N Abboud, Keith Stockerl-Goldstein, Geoffrey L Uy, Brenda J Grossman, Peter Westervelt, John F DiPersio
CD34(+)-selected stem cell boost (SCB) without conditioning have recently been utilized for poor graft function (PGF) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) with promising results. Unfortunately, many patients have been unable to receive the boost infusion as their donors were unwilling or unable to undergo an additional stem cell collection. Therefore, we conducted this study utilizing either fresh or cryopreserved peripheral blood stem cell products to create CD34(+)-selected boost infusions for the treatment of PGF...
March 17, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28315401/a-new-style-of-transplantation-may-gain-points-when-treating-older-patients-with-acute-myelogenous-leukemia
#7
Aaron T Gerds, Sudipto Mukherjee
No abstract text is available yet for this article.
March 14, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28315400/multicolor-flow-cytometry-and-multi-gene-next-generation-sequencing-are-complementary-and-highly-predictive-for-relapse-in-acute-myeloid-leukemia-following-allogeneic-transplant
#8
Bartlomiej M Getta, Sean M Devlin, Ross L Levine, Maria E Arcila, Abhinita S Mohanty, Ahmet Zehir, Martin S Tallman, Sergio A Giralt, Mikhail Roshal
Minimal Residual disease (MRD) in acute myeloid leukemia (AML) is typically measured using multi-parameter flow cytometry (MFC). Detection of leukemia mutations using multi-gene next generation sequencing (NGS) can potentially be used to measure residual disease. We used a targeted 28-gene NGS panel to detect mutations and different-from-normal 10-colour MFC to measure MRD in AML patients before allogeneic hematopoietic stem cell transplant (HCT). Residual disease was defined when any abnormal blast population was detected using MFC and when any leukemia allele was detected with a variant allele frequency (VAF) ≥5% using NGS...
March 14, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28302584/uncertainty-of-physicians-and-patients-in-medical-decision-making
#9
EDITORIAL
Tejaswini Dhawale, Lotte M Steuten, H Joachim Deeg
Modern medicine has developed an apparently unlimited array of diagnostic and therapeutic tools. Treatment options, for example for patients with hematologic malignancies, are expanding rapidly. These developments, offering a spectrum of modalities, provide a new outlook on successful treatment for many patients. However, for any individual patient, decisions as to the optimum treatment strategy remain challenging as all prognostic projections are based on statistics. The challenge lies in the identification of parameters that characterize individual patients as prospective responders or non-responders and, hence, determine the prognosis...
March 13, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28288952/outcomes-after-umbilical-cord-blood-transplantation-for-myelodysplastic-syndromes
#10
Aaron T Gerds, Kwang Woo Ahn, Zhen-Huan Hu, Hisham Abdel-Azim, Gorgun Akpek, Mahmoud Aljurf, Karen K Ballen, Amer Beitinjaneh, Ulrike Bacher, Jean-Yves Cahn, Saurabh Chhabra, Corey Cutler, Andrew Daly, Zachariah DeFilipp, Robert Peter Gale, Usama Gergis, Michael R Grunwald, Gregory A Hale, Betty Ky Hamilton, Madan Jagasia, Rammurti T Kamble, Tamila Kindwall-Keller, Taiga Nishihori, Richard F Olsson, Muthalagu Ramanathan, Ayman A Saad, Melhem Solh, Celalettin Ustun, David Valcárcel, Erica Warlick, Baldeep M Wirk, Matt Kalaycio, Edwin Alyea, Uday Popat, Ronald Sobecks, Wael Saber
For patients with hematologic malignancies undergoing allogeneic hematopoietic cell transplantation, umbilical cord blood transplantation (UCBT) has become an acceptable alternative donor source in the absence of a matched sibling or unrelated donor. However, there have been few published series dedicated solely to describing the outcomes of adult patients with myelodysplastic syndrome (MDS) who have undergone UCBT. From 2004 to 2013, 176 adult MDS patients underwent UCBT as reported to the Center for International Blood and Marrow Transplant Research...
March 10, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28288951/haploidentical-related-donor-hematopoietic-stem-cell-transplantation-for-dock8-deficiency-using-post-transplantation-cyclophosphamide
#11
Nirali N Shah, Alexandra F Freeman, Helen Su, Kristen Cole, Mark Parta, Niki M Moutsopoulos, Safa Baris, Elif Karakoc-Aydiner, Thomas E Hughes, Heidi H Kong, Steve M Holland, Dennis D Hickstein
Dedicator-of-Cytokinesis-8 (DOCK8) deficiency, a primary immunodeficiency disease, can be reversed by allogeneic hematopoietic stem cell transplant (HSCT); however, there are few reports describing the use of alternative donor sources for HSCT in DOCK8 deficiency. We describe HSCT for patients with DOCK8 deficiency who lack a matched related or unrelated donor using bone marrow from haploidentical related donors and post-transplantation cyclophosphamide (PT/CY) for GVHD prophylaxis. Seven patients with DOCK8 deficiency (median age 20 years, range 7-25 years) received a haploidentical related donor HSCT...
March 10, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28288950/do-patients-and-physicians-agree-when-they-assess-quality-of-life
#12
A Barata, R Martino, I Gich, I García-Cadenas, E Abella, P Barba, J Briones, S Brunet, A Esquirol, F García-Pallarols, A Garrido, M Granell, J Martinez, I Mensa, S Novelli, B Sanchez-Blanco, D Valcárcel, J Sierra
INTRODUCTION: Patients and physicians agreement on the most significant symptoms is associated with treatment outcomes and satisfaction with care. Thus, we seek to assess patient and physician agreement on patient-reported quality of life (QoL), and whether patient-related variables predicted disagreement. METHODS: This is a cross-sectional, multisite study; where patients and physicians completed the FACT-BMT at day 90. Agreement was analyzed with the Intraclass Coefficient Correlation (ICC)...
March 10, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28288949/evaluation-of-the-pharmacokinetics-and-efficacy-of-a-busulfan-test-dose-in-adult-patients-undergoing-myeloablative-hematopoietic-cell-transplant
#13
Elizabeth Weil, Felicia Zook, Carolyn Oxencis, Angela Canadeo, Angela Urmanski, Mindy Waggoner, Daniel Eastwood, Marcelo Pasquini, Mehdi Hamadani, Parameswaran Hari
Due to inter-patient variability in busulfan exposure, therapeutic monitoring of busulfan is often employed in myeloablative allogeneic transplantation to ensure that patients are near the optimal steady state goal of 900 ng/mL. One challenge with therapeutic monitoring of busulfan is the brief course of treatment busulfan is administered over, so prompt analysis and dose adjustments are necessary. Pharmacokinetic evaluation of a busulfan test dose prior to beginning the conditioning regimen would allow for all conditioning regimen doses to be given at the calculated optimized dose...
March 10, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28286199/abnormalities-of-the-bone-marrow-immune-microenvironment-in-patients-with-prolonged-isolated-thrombocytopenia-after-allogeneic-hematopoietic-stem-cell-transplantation
#14
Yang Song, Min-Min Shi, Yuan-Yuan Zhang, Xiao-Dong Mo, Yu Wang, Xiao-Hui Zhang, Lan-Ping Xu, Xiao-Jun Huang, Yuan Kong
Prolonged isolated thrombocytopenia (PT) is a serious complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, whether abnormalities of the bone marrow immune microenvironment are involved in the pathogenesis of PT remains unknown. In total, 20 patients with PT, 40 matched patients with good graft function (GGF) after allo-HSCT, and 20 healthy donors (HD) were enrolled in this nested case-control study. Th1, Th2, Tc1, Tc2, Th17 and Treg cells were analysed by flow cytometry, and IFN-γ, IL-4, IL-17, IL-6, IL-21 and thrombopoietin levels in bone marrow (BM) plasma were evaluated using cytometric beads assay and enzyme-linked immunosorbent assay...
March 9, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28286198/in-hospital-mortality-and-post-transplant-complications-in-elderly-multiple-myeloma-patients-undergoing-autologous-hematopoietic-stem-cell-transplantation-a-population-based-study
#15
Larysa Sanchez, Michael Sylvester, Ricardo Parrondo, Veronica Mariotti, Jean Anderson Eloy, Victor T Chang
Autologous hematopoietic stem cell transplantation (auto-HSCT) has improved survival in patients with multiple myeloma (MM) and is increasingly used in elderly patients. The aim of this study was to characterize and compare in-hospital complications and mortality after auto-HSCT in younger (< age 65) vs. elderly (≥ age 65) MM patients utilizing the Nationwide Inpatient Sample (NIS). Over a three-year period (2008-2010), 2209 patients with MM were admitted to U.S. Hospitals for auto-HSCT. The median age was 59 years, with 1650 patients (74...
March 9, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28286197/a-lot-to-learn-about-allogeneic-hematopoietic-cell-transplantation-for-chronic-myelomonocytic-leukemia
#16
Guillermo F Sanz
No abstract text is available yet for this article.
March 9, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28285082/response-assessment-in-myeloma-practical-manual-on-consistent-reporting-in-an-era-of-dramatic-therapeutic-advances
#17
Laurent Garderet, Anita D'Souza, Paulette Jacobs, Anja van Biezen, Stefan Schönland, Nicolaus Kroeger, Curly Morris, Parameswaran Hari
The understanding and treatment of multiple myeloma have dramatically improved in the last years. However, accurate assessment of the response of myeloma to therapy and its subsequent relapse remains a difficult task. Criteria have changed over time and new parameters have recently been incorporated to evaluate the minimal residual disease status. We present a practical approach to assess response and relapse/progression in myeloma in the context of its treatment. A robust reporting schema is crucial to correctly evaluate any treatment protocol and do cross trial comparisons...
March 8, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28285081/a-phase-i-trial-of-high-dose-lenalidomide-and-melphalan-as-conditioning-for-autologous-stem-cell-transplantation-in-relapsed-or-refractory-multiple-myeloma
#18
Tomer M Mark, Danielle Guarneri, Peter Forsberg, Adriana Rossi, Roger Pearse, Arthur Perry, Karen Pekle, Linda Tegnestam, June Greenberg, Tsiporah Shore, Usama Gergis, Sebastian Mayer, Koen Van Besien, Scott Ely, David Jayabalan, Daniel Sherbenou, Morton Coleman, Ruben Niesvizky
Autologous stem cell transplantation (ASCT) conditioned with high-dose chemotherapy has long been established as the standard of care for eligible patients with newly diagnosed multiple myeloma. In spite of recent therapeutic advances, high-dose melphalan (HDM) remains the chemotherapy regimen of choice in this setting. Lenalidomide (LEN) in combination with low-dose dexamethasone is recognized as a standard of care for patients with relapsed or refractory multiple myeloma (RRMM), and there is growing support for the administration of LEN as maintenance therapy post-ASCT...
March 8, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28285080/early-hyperglycemia-after-initiation-of-glucocorticoid-therapy-predicts-adverse-outcome-in-patients-with-acute-graft-versus-host-disease
#19
Melanie N Stauber, Felix Aberer, Abderrahim Oulhaj, Julia K Mader, Armin Zebisch, Thomas R Pieber, Peter Neumeister, Hildegard T Greinix, Heinz Sill, Harald Sourij, Albert Wölfler
Due to first-line treatment with high-dose glucocorticoids (GC), steroid-induced hyperglycemia develops frequently in patients with acute graft-versus-host disease (aGvHD) potentially impacting on their outcome. We performed a retrospective analysis on 104 patients who received systemic GC for aGvHD and investigated the consequences of aberrant glucose metabolism. In particular, we focused on glucose parameters early after initiation of GC. With a median of 50 (range 4-513) blood glucose measurements during GC treatment, increasing mean, median and maximum glucose levels as well as the need for insulin treatment were associated with decreased overall survival (OS) in simple and multiple survival analysis...
March 8, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28285079/defibrotide-for-patients-with-hepatic-veno-occlusive-disease-sinusoidal-obstruction-syndrome-vod-sos-interim-results-from-a-treatment-ind-study
#20
Paul G Richardson, Angela R Smith, Brandon M Triplett, Nancy A Kernan, Stephan A Grupp, Joseph H Antin, Leslie Lehmann, Tsiporah Shore, Massimo Iacobelli, Maja Miloslavsky, Robin Hume, Alison L Hannah, Bijan Nejadnik, Robert J Soiffer
Hepatic veno-occlusive disease, or sinusoidal obstruction syndrome (VOD/SOS), is a serious and potentially fatal complication of conditioning for hematopoietic stem cell transplantation (HSCT) or of chemotherapy regimens alone. Defibrotide is a complex mixture of single-stranded polydeoxyribonucleotides that is approved in the United States for treatment of hepatic VOD/SOS with renal or pulmonary dysfunction post-HSCT and in the European Union, Israel, and South Korea for treatment of severe hepatic VOD/SOS post-HSCT...
March 8, 2017: Biology of Blood and Marrow Transplantation
journal
journal
20050
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"